56 related articles for article (PubMed ID: 35397511)
1. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract][Full Text] [Related]
2. Tivozanib in renal cell carcinoma: a new approach to previously treated disease.
Salgia NJ; Zengin ZB; Pal SK
Ther Adv Med Oncol; 2020; 12():1758835920923818. PubMed ID: 32547647
[TBL] [Abstract][Full Text] [Related]
3. Tivozanib: current status and future directions in the treatment of solid tumors.
Pal SK; Bergerot PG; Figlin RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1851-9. PubMed ID: 23013465
[TBL] [Abstract][Full Text] [Related]
4. Novel quinazolines bearing 1,3,4-thiadiazole-aryl urea derivative as anticancer agents: design, synthesis, molecular docking, DFT and bioactivity evaluations.
Masoudinia S; Samadizadeh M; Safavi M; Bijanzadeh HR; Foroumadi A
BMC Chem; 2024 Feb; 18(1):30. PubMed ID: 38347613
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions.
Sammarco E; Manfredi F; Nuzzo A; Ferrari M; Bonato A; Salfi A; Serafin D; Zatteri L; Antonuzzo A; Galli L
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370782
[TBL] [Abstract][Full Text] [Related]
6. Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma.
Sakellakis M; Zakopoulou R
Cureus; 2023 Mar; 15(3):e35675. PubMed ID: 37012938
[TBL] [Abstract][Full Text] [Related]
7. Tivozanib: practical implications for renal cell carcinoma and other solid tumors.
Berge EM; Bowles DW; Flaig TW; Lam ET; Jimeno A
Drugs Today (Barc); 2013 May; 49(5):303-15. PubMed ID: 23724410
[TBL] [Abstract][Full Text] [Related]
8. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
Mehta A; Sonpavde G; Escudier B
Future Oncol; 2014 Aug; 10(11):1819-26. PubMed ID: 25325825
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
Chang E; Weinstock C; Zhang L; Fiero MH; Zhao M; Zahalka E; Ricks TK; Fourie Zirkelbach J; Qiu J; Yu J; Chen XH; Bhatnagar V; Goldberg KB; Tang S; Kluetz PG; Pazdur R; Ibrahim A; Beaver JA; Amiri-Kordestani L
Clin Cancer Res; 2022 Feb; 28(3):441-445. PubMed ID: 34417198
[TBL] [Abstract][Full Text] [Related]
10. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Rini BI; Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; McDermott DF
Lancet Oncol; 2020 Jan; 21(1):95-104. PubMed ID: 31810797
[TBL] [Abstract][Full Text] [Related]
11. Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
Wright KM
Oncology (Williston Park); 2020 Jul; 34(7):257. PubMed ID: 32674211
[TBL] [Abstract][Full Text] [Related]
12. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Meza L; McDermott DF; Escudier B; Hutson TE; Porta C; Verzoni E; Atkins MB; Kasturi V; Pal SK; Rini B
Oncologist; 2023 Mar; 28(3):e167-e170. PubMed ID: 36576430
[TBL] [Abstract][Full Text] [Related]
13. Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature.
Caquelin L; Gewily M; Mottais W; Tebaldi C; Laviolle B; Naudet F; Locher C
BMC Cancer; 2022 Apr; 22(1):381. PubMed ID: 35397511
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
